Literature DB >> 8232780

Reversal of brain atrophy with biotin treatment in biotinidase deficiency.

D P Bousounis1, P R Camfield, B Wolf.   

Abstract

Two children with biotinidase deficiency presented with seizures at 2 months of age. The first child had a fluctuating course with continual developmental progress and cessation of seizures despite symptoms of chronic neurologic dysfunction until he was diagnosed at 17 months. The second child had a progressive course with uncontrolled seizures leading to an unresponsive state until she was diagnosed at 6 1/2 months. Neither child had dermatologic symptoms until shortly before the time of diagnosis. Both children improved markedly with biotin treatment. Serial CT-scan and MRI studies of the brain showed a distinct pattern of changes. Shortly after initial presentation, diffuse low attenuation of the white matter was seen followed by progressive marked cerebral atrophy, which was reversed following biotin treatment. Because this is a reversible condition, clinicians should screen for biotinidase deficiency in all children with symptoms of chronic neurologic dysfunction, especially when radiologic findings of low attenuation of the white matter are followed by cerebral atrophy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232780     DOI: 10.1055/s-2008-1071543

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  6 in total

1.  Biotinidase deficiency--a treatable entity.

Authors:  S Gulati; G R Passi; A Kumar; M Kabra; V Kalra; I C Verma
Journal:  Indian J Pediatr       Date:  2000-06       Impact factor: 1.967

Review 2.  Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease.

Authors:  Katharina Danhauser; Jan A M Smeitink; Peter Freisinger; Wolfgang Sperl; Hemmen Sabir; Berit Hadzik; Ertan Mayatepek; Eva Morava; Felix Distelmaier
Journal:  J Inherit Metab Dis       Date:  2015-02-17       Impact factor: 4.982

3.  Cerebral metabolic changes in biotinidase deficiency.

Authors:  M Schürmann; V Engelbrecht; K Lohmeier; H G Lenard; U Wendel; J Gärtner
Journal:  J Inherit Metab Dis       Date:  1997-11       Impact factor: 4.982

4.  Biotin-responsive basal ganglia disease: neuroimaging features before and after treatment.

Authors:  H Kassem; A Wafaie; S Alsuhibani; T Farid
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-08       Impact factor: 3.825

5.  Biotinidase deficiency: the importance of adequate follow-up for an inconclusive newborn screening result.

Authors:  Trevor L Hoffman; Erin M Simon; Can Ficicioglu
Journal:  Eur J Pediatr       Date:  2005-02-15       Impact factor: 3.860

6.  Biotinidase Deficiency: New Directions and Practical Concerns.

Authors:  Barry Wolf
Journal:  Curr Treat Options Neurol       Date:  2003-07       Impact factor: 3.972

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.